Call us: + 31 (0)20 - 4350 580

Home > News

The growing challenge of handling multistream data capture in clinical trials - ACDM 2019

The growing challenge of handling multistream data capture in clinical trials - ACDM 2019
18 March 2019 - José Matamoros Luna MSc, Clinical Data Manager

This year's annual conference of the Association for Clinical Data Management (ACDM) took place in Amsterdam. During a two-day event, the emphasis was on the growing challenges of multistream data capture in clinical trials, wi...

Read more

SMS-oncology sets out to improve patient recruitment for clinical trials

SMS-oncology sets out to improve patient recruitment for clinical trials
18 February 2019 - Wendy Onstenk MD PhD

Drug development crucially relies on accurately designed and well recruiting clinical trials. However, low accrual rates of clinical trials and unmet recruitment targets have been global attention points for many years. A 70-80...

Read more

EMA & FDA Anti-cancer Drugs Recommendations for Approval in 2018

EMA & FDA Anti-cancer Drugs Recommendations for Approval in 2018
25 January 2019 - Chelsea McLean PhD, Roy Feenstra, Yuva Oz MSc

In 2018, EMA and FDA made a total of 44 positive recommendations for anti-cancer medicines to receive marketing approval.

Read more

ESMO 2018: Immunotherapy and other stories

ESMO 2018: Immunotherapy and other stories
26 October 2018 - Nadina Grosios PhD MPH, Director Consultancy

ESMO 2018: Immunotherapy and other stories The annual European Society for Medical Oncology (ESMO) 2018 Congress took place from 19-23 October 2018 in breathtaking Munich, Germany. Held under the tagline "Securing access to op...

Read more

Combination immunotherapy: The latest revolution in cancer treatment

Combination immunotherapy: The latest revolution in cancer treatment
13 September 2018 - Romy Krikke BSc

An analysis of the clinical landscape The present focus in the treatment of cancer is immunotherapy, in particular immunotherapies that are trialed in a combination regimen. By combining immuno-oncology (IO) agents with oth...

Read more
Read more blog items